Key result
Cancer is associated with a complex thrombophilic state driven by specific pathogenetic mechanisms and clinical risk factors that predispose patients to thromboembolism.
This review summarizes the biology, incidence, and risk factors for thromboembolism in patients with cancer.
Underscores VTE awareness in cancer care; leaves open prospective validation of risk models for targeted prophylaxis.
The association between malignancy and thrombosis has long been appreciated but remains incompletely understood. This is the first of a two-part review of the complex, integral relationship between these two entities, and addresses the mechanisms and pathogenesis of this relationship and the clinical risk factors for thromboembolism in cancer patients.
No takes yet. Share an insight, caveat, or question.
DiPasco et al. (2011) studied this question. Cancer is associated with a complex thrombophilic state driven by specific pathogenetic mechanisms and clinical risk factors that predispose patients to thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: